Your session is about to expire
← Back to Search
Monoclonal Antibodies
RO7566802 + Atezolizumab for Advanced Solid Tumors
Phase 1
Recruiting
Research Sponsored by Genentech, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group
Summary
This trial is the first time a new drug called RO7566802 is being tested on humans. The study will look at how safe and effective the drug is, both by itself and when used with
Who is the study for?
This trial is for adults with advanced solid tumors that have grown despite treatment, or when standard treatment isn't suitable. Participants should be in good physical condition (ECOG 0-1), expected to live at least 3 months, and have proper organ function. They must provide a tumor sample if needed.
What is being tested?
The study tests RO7566802 alone and combined with Atezolizumab to assess safety and early cancer-fighting ability. It's a two-stage process: first finding the right dose (dose escalation) then seeing how well it works (expansion).
What are the potential side effects?
Possible side effects include typical reactions to immunotherapy like fatigue, skin reactions, inflammation of organs, flu-like symptoms, changes in blood counts or chemistry which could indicate liver or kidney issues.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Group I: Dose Expansion CohortExperimental Treatment2 Interventions
Participants with select solid tumors will receive a recommended dose of RO7566802, determined in Dose Escalation phase, as an IV infusion in combination with a fixed dose of atezolizumab, as an IV infusion on Day 1 of each 21-day cycle until disease progression or unacceptable toxicity.
Group II: Dose Escalation CohortExperimental Treatment2 Interventions
Participants in successive cohorts will receive escalating doses of RO7566802, as an intravenous (IV) infusion on Day 1 of each 21-day cycle followed by RO7566802 in combination with a fixed dose of atezolizumab, as an IV infusion on Day 1 of each 21-day cycle until disease progression or unacceptable toxicity.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Atezolizumab
2016
Completed Phase 3
~5860
Find a Location
Who is running the clinical trial?
Genentech, Inc.Lead Sponsor
1,565 Previous Clinical Trials
569,750 Total Patients Enrolled
Clinical TrialsStudy DirectorHoffmann-La Roche
2,233 Previous Clinical Trials
901,987 Total Patients Enrolled